Pharmaceuticals
News Category
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics has fully repaid its revolving credit facility drawn to finance the Paladin acquisition, using operational cash flow, while mainta...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates former Eli Lilly executive Stephen Fry to its board, bringing expertise in organizational transformation and performance culture to su...
LIXTE Biotechnology's LB-100: The World's Only Clinical-Stage PP2A Inhibitor Poised to Transform Cancer Treatment
LIXTE Biotechnology's lead compound LB-100, the only clinical-stage PP2A inhibitor, enhances cancer cell sensitivity to therapy and disrupts DNA repai...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Highlights Transformational Year with Clinical and Strategic Advances
LIXTE Biotechnology Holdings filed its 2025 annual report, detailing leadership changes, expanded clinical trials for its lead compound LB-100, the ac...
PolyPeptide Shareholders Approve All Proposals at Annual General Meeting 2026
PolyPeptide Group AG announced that shareholders approved all board proposals at its fifth annual general meeting, including re-election of directors ...
Soligenix Pioneers Platform-Based Drug Development with Synthetic Hypericin Across Multiple Indications
Soligenix exemplifies efficient drug development by leveraging its synthetic hypericin platform for both cutaneous T-cell lymphoma and psoriasis, redu...
LIXTE Biotechnology's LB-100 Aims to Enhance Chemotherapy and Immunotherapy Effectiveness
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor, as a novel approach to make tumors more responsive to existing canc...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Iodine and Barium Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals is evaluating three U.S. sites for a vertically integrated contrast media manufacturing facility, aiming to reduce costs and ...
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
Lantern Pharma has expanded its predictBBB platform into a Large Quantitative Model, offering researchers a real-time molecular intelligence engine fo...
Tonix Pharmaceuticals to Present at Two Investor Conferences in May
Tonix Pharmaceuticals (NASDAQ: TNXP) will showcase its CNS and immunology pipeline at the RBC Capital Markets Global Healthcare Conference and A.G.P.’...
NanoViricides Advances NV-387 Toward Phase II Clinical Trials for MPox in Democratic Republic of Congo
NanoViricides reported progress on its broad-spectrum antiviral NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orph...
Lantern Pharma Raises $4.4 Million in Registered Direct Offering to Advance AI-Driven Oncology Pipeline
Lantern Pharma closed a $4.4 million registered direct offering, with potential additional proceeds from warrants, to support its AI-powered precision...
NanoViricides Prices $2 Million Registered Direct Offering
NanoViricides announced a $2 million registered direct offering with a single institutional investor, issuing common shares and warrants, to fund its ...
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Powered Antibody Discovery
Sino Biological's new XPressMAX™ Cell-Free Protein Synthesis Kit enables ultra-fast protein synthesis in three hours, supporting AI-driven high-throug...
Earth Science Tech Inc. Builds Vertically Integrated Telehealth and Pharmacy Ecosystem
Earth Science Tech Inc. (ETST) is transforming into a diversified holding company with a new telemedicine platform and pharmacy operations, emphasizin...
Carmed Pharmaceuticals Leverages CityBiz Feature to Boost U.S. Expansion
Carmed Pharmaceuticals, a Turkey-based maker of standardized carvacrol-based formulations, is advancing its U.S. market entry through a CityBiz Q&A wi...
Redwood AI Corp. Gains DTC Eligibility and Engages IBN for Investor Awareness
Redwood AI Corp. announced DTC eligibility for its common shares and a $114,000 engagement with InvestorBrandNetwork for market awareness services, ai...
Quantum BioPharma's Multiple Sclerosis Program Advances to IND Submission Stage
Quantum BioPharma Ltd. progresses its clinical-stage multiple sclerosis program toward Phase 2 trials, supported by a diversified portfolio spanning t...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities on BioMedWire Podcast
Quantum BioPharma's lead drug candidate Lucid-MS aims to address mobility loss in multiple sclerosis by targeting nerve damage, while its commercial p...
Kairos Pharma Mid-Year Update Highlights Pipeline Expansion and Clinical Milestones
Kairos Pharma's mid-year 2026 update details plans to acquire a Phase 1-ready oral c-MET inhibitor to expand its oncology pipeline and advance clinica...
Voyageur Pharmaceuticals Closes $5 Million Private Placement for Contrast Media Development
Voyageur Pharmaceuticals closed a $5 million private placement to fund FDA licensing, regulatory approvals, and project development for its barium and...
Voyageur Pharmaceuticals Submits Multi-Year Permit Application for Frances Creek Barite Project, Advancing Toward Feasibility Study
Voyageur Pharmaceuticals has submitted a multi-year exploration permit application for its Frances Creek barite project, enabling a test extraction of...